This is stated in the company's report made public in the Electronic Disclosure System of the National Securities and Stock Market Commission, Interfax-Ukraine reports.
According to the company's report, its net income from sales of products during the reporting period amounted to 1.38 billion hryvnia, which is 17 percent more than in the first half of 2017.
Darnitsa’s gross profit increased by 15 percent - up to 711,940,000 hryvnia.
In 2017, the pharmaceutical company reportedly received a net profit of 341,110,000 million hryvnia, which is 0.29 percent more than in 2016.
Darnitsa is one of ten Ukraine’s biggest pharmaceutical manufacturers and is in top ten hospital suppliers. At year-end 2016, it secured the third place among Ukrainian companies in terms of quantity of medicines sold through pharmacies after Pharmak and Arterium Corporation.
The company’s ultimate beneficial owner is Hlib Zagoriy, a member of Petro Poroshenko Bloc parliamentary faction.